Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.

Anti-cancer Drugs
Vivian E von GruenigenSteven E Waggoner

Abstract

The aim of this study was to determine the dose of weekly oral topotecan that allows safe administration and to evaluate the pharmacokinetics of this dose in patients with recurrent gynecologic malignancies. The first cohort of patients received oral topotecan 6 mg/week administered orally on days 1, 8, and 15 of a 28-day regimen. A standard 3+3 dose-escalating phase design was used for dose levels II-V (8, 10, 12 and 14 mg/week). Toxicity was scored according to the Common Terminology Criteria for Adverse Events. Cumulative toxicity was summarized in the 6-12 mg/week combined cohort and 14 mg/week cohort separately. Pharmacokinetic samples were obtained for day 1, cycle 1 only in the expansion cohort (dose level V). Twenty-five patients received a total of 88 cycles of therapy. Hematologic toxicities of grade 3 (6-12 mg dose) were neutropenia (25%) and anemia (8.3%). Gastrointestinal toxicities of grade 3 were diarrhea (16.7%) and obstruction (8.3%, disease-related). Grade 3 or 4 (14 mg/week) hematologic toxicities consisted of neutropenia (38.5%), platelets (15.4%), anemia (15.4%), infection with neutropenia (7.7%), and thrombosis (7.7%). Gastrointestinal toxicities of grade 3 were diarrhea (7.7%), obstruction (7.7%), and vom...Continue Reading

References

Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G LiuE Warner
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C J GerritsD D von Hoff
Jul 29, 1999·British Journal of Cancer·V M HerbenJ H Schellens
Oct 6, 2000·Cancer Chemotherapy and Pharmacology·S AkhtarJ Wright
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Oct 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L Clarke-PearsonS Z Fields
May 2, 2002·Journal of the National Cancer Institute·Ann H PartridgeEric P Winer
Jun 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M F KruijtzerJ H M Schellens
Dec 19, 2002·Journal of the National Cancer Institute·Sharyn D BakerAlex Sparreboom
Feb 7, 2003·The New England Journal of Medicine·William E Evans, Howard L McLeod
May 6, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Alex SparreboomWilliam D Figg
Mar 18, 2004·Journal of the National Cancer Institute·Gordon J S RustinJan Vermorken
Mar 18, 2004·Journal of the National Cancer Institute·Michelle CronkLewis Perrin
Sep 24, 2004·Gynecologic Oncology·Tiffany A TrainaJakob Dupont
May 24, 2005·Cancer Biology & Therapy·Alex SparreboomHans Gelderblom
Sep 22, 2009·Critical Reviews in Oncology/hematology·Domenica LorussoGiovanni Scambia
Dec 17, 2009·Anti-cancer Drugs·George P StathopoulosMichael Vaslamatzis
Jun 10, 2010·Nature Reviews. Clinical Oncology·Eddy PasquierNicolas André
Nov 26, 2010·Pediatric Blood & Cancer·Jane E MinturnJean B Belasco
Dec 2, 2010·Current Pharmaceutical Biotechnology·Robert W RobeySusan E Bates

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.